First human trial of KP 511 for the treatment of severe pain

Trial Profile

First human trial of KP 511 for the treatment of severe pain

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 May 2016

At a glance

  • Drugs KP 511 (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors KemPharm
  • Most Recent Events

    • 10 May 2016 According to a KemPharm media release, KP511 has been granted Fast Track designation by the US FDA. KemPharm plans to seek approval of KP511/ER under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act with an anticipated New Drug Application (NDA) submission as early as 2018.
    • 10 May 2016 Status changed from not yet recruiting to recruiting, according to a KemPharm media release.
    • 28 Mar 2016 According to a KemPharm media release, the company has received clearance from the US FDA to initiate human clinical trials of KP511 and expect to initiate the clinical trials in the second quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top